Acasti Pharma Inc (ACST)
2.89
+0.11
(+3.96%)
USD |
NASDAQ |
May 01, 16:00
2.70
-0.19
(-6.57%)
After-Hours: 20:00
Acasti Pharma Research and Development Expense (Quarterly): 1.443M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.443M |
| September 30, 2023 | 0.46M |
| June 30, 2023 | 1.095M |
| March 31, 2023 | 1.64M |
| December 31, 2022 | 2.45M |
| September 30, 2022 | 3.292M |
| June 30, 2022 | 2.59M |
| March 31, 2022 | 2.326M |
| December 31, 2021 | 2.179M |
| September 30, 2021 | 0.585M |
| June 30, 2021 | 0.469M |
| March 31, 2021 | 1.369M |
| December 31, 2020 | 0.678M |
| September 30, 2020 | 0.915M |
| June 30, 2020 | 1.211M |
| March 31, 2020 | 3.637M |
| December 31, 2019 | 3.317M |
| September 30, 2019 | 3.954M |
| June 30, 2019 | 6.19M |
| March 31, 2019 | 9.130M |
| December 31, 2018 | 7.016M |
| September 30, 2018 | 7.065M |
| June 30, 2018 | 6.757M |
| March 31, 2018 | 4.486M |
| December 31, 2017 | 3.408M |
| Date | Value |
|---|---|
| September 30, 2017 | 2.700M |
| June 30, 2017 | 1.524M |
| November 30, 2016 | 1.253M |
| August 31, 2016 | 1.218M |
| May 31, 2016 | 1.835M |
| February 29, 2016 | 1.248M |
| November 30, 2015 | 1.612M |
| August 31, 2015 | 1.255M |
| May 31, 2015 | 1.593M |
| February 28, 2015 | 2.886M |
| November 30, 2014 | 1.527M |
| August 31, 2014 | 1.658M |
| May 31, 2014 | 1.123M |
| February 28, 2014 | 2.070M |
| November 30, 2013 | 1.205M |
| August 31, 2013 | 1.447M |
| May 31, 2013 | 0.7554M |
| February 28, 2013 | 0.8338M |
| November 30, 2012 | 0.7757M |
| August 31, 2012 | 0.7665M |
| May 31, 2012 | 0.5432M |
| February 29, 2012 | 0.49M |
| November 30, 2011 | 1.320M |
| August 31, 2011 | 0.9233M |
| May 31, 2011 | 0.4721M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.46M
Minimum
Sep 2023
6.19M
Maximum
Jun 2019
2.095M
Average
1.64M
Median
Mar 2023
Research and Development Expense (Quarterly) Benchmarks
| Aurinia Pharmaceuticals Inc | 10.23M |
| Edesa Biotech Inc | 0.7045M |
| Lexaria Bioscience Corp | 0.2458M |
| Xenon Pharmaceuticals Inc | 41.08M |
| ESSA Pharma Inc | 5.377M |